Table 2 Characteristics of the validation cohort

Number of subjects

37

11

11

15

Male sex, %

65

64

64

67

0.982^a

Age, yr

63 ± 2

68 ± 3^b

70 ± 2^b

54 ± 4^c

0.002

BMI, kg/m²

27.8 ± 1.0

28.0 ± 2.2^b

31.2 ± 2.0^b

25.2 ± 1.1^b

0.064

Glucose mmol/L

6.8 ± 0.3

6.6 ± 0.3

6.5 ± 0.6

7.2 ± 0.4

0.264

GFR ml/min

62.4 ± 6.9

62.3 ± 11.0^b

39.8 ± 8.0^b

80.4 ± 12.8^b

0.033

CRP mg/L

142.0 ± 18.8

149.4 ± 39.3^b

170.7 ± 37.4^b

115.6 ± 95.8^b

0.477

Diabetes mellitus

12/37

0/11

11/11

0/15

<0.001^a

Renal replacement therapy

3/37

1/11

1/11

1/15

0.965^a

APACHE II score

21 (18–28)

20^b (18–25)

27^b (20–33)

21^b (15–26)

0.185

SAPS II

49 (37.0–64.5)

48^b (42.0–65.0)

63^b (48.0–71.0)

45^b (31.0–54.0)

0.112

28-day mortality, n (%)

10/37 (27)

4/11 (36)

2/11 (18)

4/15 (27)

0.628^a